Patent US4887775A successfully refreshed from Google Patents.
US4698342A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method and compositions for controlling pain, depression and sedation
Assignee: SEROTONIN INDUSTRIES CHARLESTON A LP
•
Filing: 1986-05-20
•
Granted: 1987-10-06
•
Expires: 2006-05-20
Abstract
Abstract Compositions are disclosed for controlling pain, depression, and sedation. The compositions comprise a serotonin precursor such as L-tryptophan or L-5-hydroxytryptophan in combination with a serotonin-specific reuptake inhibitor such as trazodone. In a preferred embodiment, the compositions are coadministered with a narcotic, the composition substantially potentiating the analgesic effect of the narcotic.
Inventors
- 👤 Martin G. Crosby
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-10 00:30
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/496
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
105 words
A method for controlling pain, depression, or sedation in an animal comprising co-administering to said animal (1) a composition comprising a serotonin precursor selected from the group consisting of L-tryptophan, L-5-hydroxy tryptophan, and pharmaceutically acceptable salts of L-tryptophan and L-5-hydroxy tryptophan in an amount effective to increase the brain serotonin to a supra normal level, in combination with a serotonin-specific reuptake inhibitor in an amount sufficient to inhibit the reuptake of serotonin, and (2) a narcotic selected from those compounds which achieve analgesia through the mode of enhancement of brain serotonin levels, said narcotic administered in an amount effective to produce analgesia in said animal.
Claim 2
Independent Claim
105 words
A method for controlling pain, depression, or sedation in an animal comprising co-administering to said animal (1) a composition comprising a serotonin precursor selected from the group consisting of L-tryptophan, L-5-hydroxy tryptophan, and pharmaceutically acceptable salts of L-tryptophan and L-5-hydroxy tryptophan in an amount effective to increase the brain serotonin to a supra normal level, in combination with a serotonin-specific reuptake inhibitor in an amount sufficient to inhibit the reuptake of serotonin, and (2) a narcotic selected from those compounds which achieve analgesia through the mode of enhancement of brain serotonin levels, said narcotic administered in an amount effective to produce analgesia in said animal.
Claim 3
Dependent Claim
38 words
The method of claim 1 wherein said composition further includes at least one of pyridoxine, ascorbic acid, or a pharmaceutically acceptable salt of pyridoxine or ascorbic acid in an amount effective to enzymatically cofactor the biosynthesis of serotonin.
Claim 4
Dependent Claim
24 words
The method of claim 1 wherein said narcotic is selected from the group consisting of codeine, oxycodone, propoxyphene, pentazocine, morphine, meperidine, levorphanol, and methadone.
Claim 5
Dependent Claim
11 words
The method of claim 1 wherein said animal is a human.
Claim 6
Dependent Claim
47 words
The method of claim 1 or 2, wherein said serotonin precursor is selected from the group consisting of L-tryptophan, L-5-hydroxytryptophan, and pharmaceutically acceptable salts of L-tryptophan and L-5-hydroxytryptophan and said serotonin-specific reuptake inhibitor is selected from the group consisting of trazodone and pharmaceutically acceptable salts of trazodone.
Claim 7
Dependent Claim
49 words
The method of claim 1 wherein said composition comprises per part by weight of said serotoninspecific reuptake inhibitor or an equivalent amount of the pharmaceutically acceptable salt thereof, 0.5-500 parts by weight of said serotonin precursor or an equivalent amount of the pharmaceutically acceptable salt of said serotonin precursor.
Claim 8
Dependent Claim
94 words
The method of claim 2 wherein said composition comprises, per part by weight of said serotonin-specific reuptake inhibitor or an equivalent amount of the pharmaceutically acceptable salt of said serotonin-specific reuptake inhibitor, 0.5-500 parts by weight of said serotonin precursor or an equivalent amount of the pharmaceutically acceptable salt of said serotonin precursor, 0.01-10 parts by weight of said pyridoxine or an equivalent amount of the pharmaceutically acceptable salt of said pyridoxine, and 0.1-30 parts by weight of said ascorbic acid or an equivalent amount of the pharmaceutically acceptable salt of said ascorbic acid.
Claim 9
Independent Claim
96 words
The method of claims 1 or 2, wherein said composition is administered to said animal 1-4 times per day, each unit dose containing 25-200 mg of said serotonin-specific reuptake inhibitor or an equivalent amount of the pharmaceutically acceptable salt thereof, 250-4000 mg of said serotonin precursor or an equivalent amount of the pharmaceutically acceptable salt of said serotonin precursor, 10-100 mg of said pyridoxine or an equivalent amount of the pharmaceutically acceptable salt of said pyridoxine, and 50-500 mg of said ascorbic acid or an equivalent amount of the pharmaceutically acceptable salt of said ascorbic acid.
Claim 10
Dependent Claim
44 words
The method of claim 8, wherein said composition comprises, per unit dose, 150 mg trazodone, 2 gm L-tryptophan, 50 mg pyridoxine, and 250 mg ascorbic acid and is administered 4 times per day, in combination with an amount of narcotic effective to achieve analgesia.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-10-05 | 1991-04-06 | 1991-10-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-10-05 | 1995-04-06 | 1995-10-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-10-05 | 1999-04-06 | 1999-10-06 | $7700.00 | Window Closed / Lapsed |